Oruka Therapeutics ORKA Insider Ownership

NASDAQ ORKA

$109.50 +4.94 (+4.72%)

At close: Nov 10, 2026 · 4:00 PM EST

Insider Holdings by Owner

7.39Mn Shares

Healthcare Capital Partners Iii, L.P. Venrock4.15Mn56.2%

Funds Management Llc Fairmount1.13Mn15.3%

Lawrence Otto Klein923.13K12.5%

Funds, Lp Funicular333.36K4.5%

Laura Lee Sandler235.48K3.2%

Other insiders (9)612.91K8.3%

Insider Ownership Statistics

as of 30 Sep, 2026

Insider Ownership

10.58%

▼-0.132% pp QoQ

Shares Held by Insiders

6.65Mn

filed for Sep 2026

▼-1.23% QoQ

Shares Outstanding

62.87Mn

62,872,318 shares

Direct Holdings

1.37Mn

Indirect: 5.28Mn

Net Open-Market Trades

-3.76Mn

net sold · -$319.84Mn in Sep 2026

Insiders Holding Shares

with Form 4 holdings on file

Shares Owned by Insiders

Shares held % of outstanding

Latest —

Average ownership —

Peak ownership —

Open-Market Insider Trades

Bought Sold

Latest quarter —

Net over range —

Net-buying quarters —

Insider Ownership Summary

Updated Nov 4, 2026

Over the trailing 12 months, ORKA insiders sold $340.07 million worth of shares (4.08Mn shares) in open-market trades, with no open-market purchases.

Oruka Therapeutics' open-market sales in the past 12 months came from 7 insiders; no insider bought.
Fairmount Funds Management LLC (Director and 10% owner) sold the most Oruka Therapeutics stock on the open market over the past 12 months, $300.01 million (3.55Mn shares), most recently on July 1, 2026.
The latest open-market trade on record is a sale of 25K shares for $2.39 million by Lawrence Otto Klein (Chief Executive Officer) on November 2, 2026.
Apart from open-market trades, ORKA insiders received 226.7K shares in stock awards and acquired 3.97Mn shares through option exercises and conversions in the past 12 months.
According to Business Quant data, insiders at Oruka Therapeutics reported 6.65Mn shares in total in their latest Form 4 filings, or 10.58% of the 62.87Mn shares outstanding; that total is down 1.23% from 6.74Mn shares at the end of Q2 2026 and up 21.84% from 5.46Mn shares at the end of Q3 2025.
Oruka Therapeutics insiders hold 1.37Mn shares directly (20.64% of their total) and 5.28Mn shares (79.36%) indirectly, through entities such as trusts and partnerships.
The insider holdings in Oruka Therapeutics belong to 9 insiders who have reported on Form 4 within the past two years.
ORKA's three largest insider shareholders, per their latest Form 4 filings, are Venrock Healthcare Capital Partners III, L.P. (10% owner, 4.15Mn shares), Fairmount Funds Management LLC (Director and 10% owner, 1.13Mn shares) and Lawrence Otto Klein (Chief Executive Officer, 923.13K shares).
The largest insider, Venrock Healthcare Capital Partners III, L.P., holds 62.35% of ORKA's insider total.
Over the trailing 12 months, 11 insiders reported transactions in ORKA stock across 56 Form 4 filings.
These insider figures for Oruka Therapeutics are based on Form 4 filings through November 2, 2026.

Form 4 Holdings

Insiders Holding ORKA

Insiders 14

Shares held 7.39Mn

Of outstanding 11.75%

#	Insider	Position	Direct	Indirect	Total	Share of Insiders	Last Filed
1	Healthcare Capital Partners Iii, L.P. Venrock	TenPercentOwner	0	4,148,428	4,148,428	56.2%	27 Feb, 2025
2	Funds Management Llc Fairmount	Director, TenPercentOwner	0	1,131,954	1,131,954	15.3%	01 Jul, 2026
3	Lawrence Otto Klein	Chief Executive Officer	923,128	0	923,128	12.5%	02 Nov, 2026
4	Funds, Lp Funicular	TenPercentOwner, Other	333,358	0	333,358	4.5%	19 Dec, 2022
5	Laura Lee Sandler	Chief Operating Officer	235,478	0	235,478	3.2%	15 Sep, 2026
6	Fund, Lp Funicular	Other	215,029	0	215,029	2.9%	25 May, 2022
7	Henderson Group Plc Janus	TenPercentOwner	0	176,427	176,427	2.4%	20 Aug, 2024
8	Larry Todd Edwards	Chief Commercial Officer	100,000	0	100,000	1.4%	25 Aug, 2026
9	Carl Dambkowski	Director	38,743	0	38,743	0.5%	12 Jun, 2026
10	Joana Goncalves	Chief Medical Officer	31,771	0	31,771	0.4%	15 Oct, 2026
11	Paul T Quinlan	General Counsel	29,995	0	29,995	0.4%	20 Oct, 2026
12	Arjun Agarwal	Senior Vice President, Finance	14,219	0	14,219	0.2%	13 Oct, 2026
13	Thomas A Keuer	Chief Operating Officer	3,394	0	3,394	0.0%	09 Dec, 2022
14	C. Jeffrey Dekker	Chief Financial Officer	3,333	0	3,333	0.0%	09 Dec, 2022

Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.

Form 4 Filings

612 Insider Transactions

Source SEC Form 4

Latest quarter Sep 2026

Date	Insider	Position	Transaction	Shares	Price	Value	Shares Held After	Ownership
02 Nov, 2026	Lawrence Otto Klein	Chief Executive Officer	Acquired M	25,000	$7.80	$195.00K	948,128	Direct
02 Nov, 2026	Lawrence Otto Klein	Chief Executive Officer	Disposed S	6,466	$94.77	$612.79K	941,662	Direct
02 Nov, 2026	Lawrence Otto Klein	Chief Executive Officer	Disposed S	15,036	$95.64	$1.44Mn	926,626	Direct
02 Nov, 2026	Lawrence Otto Klein	Chief Executive Officer	Disposed S	2,442	$96.70	$236.15K	924,184	Direct
02 Nov, 2026	Lawrence Otto Klein	Chief Executive Officer	Disposed S	756	$97.45	$73.68K	923,428	Direct
02 Nov, 2026	Lawrence Otto Klein	Chief Executive Officer	Disposed S	300	$98.40	$29.52K	923,128	Direct
02 Nov, 2026	Lawrence Otto Klein	Chief Executive Officer	Disposed M	25,000	$0.00	$0	1,503,513	Direct
20 Oct, 2026	Paul T Quinlan	General Counsel	Acquired M	9,000	$7.80	$70.20K	38,995	Direct
20 Oct, 2026	Paul T Quinlan	General Counsel	Disposed S	400	$74.90	$29.96K	38,595	Direct
20 Oct, 2026	Paul T Quinlan	General Counsel	Disposed S	500	$76.12	$38.06K	38,095	Direct
20 Oct, 2026	Paul T Quinlan	General Counsel	Disposed S	1,000	$77.21	$77.21K	37,095	Direct
20 Oct, 2026	Paul T Quinlan	General Counsel	Disposed S	4,100	$78.79	$323.04K	32,995	Direct
20 Oct, 2026	Paul T Quinlan	General Counsel	Disposed S	3,000	$79.49	$238.47K	29,995	Direct
20 Oct, 2026	Paul T Quinlan	General Counsel	Disposed M	9,000	$0.00	$0	70,996	Direct
15 Oct, 2026	Joana Goncalves	Chief Medical Officer	Acquired M	3,500	$6.84	$23.94K	35,271	Direct
15 Oct, 2026	Joana Goncalves	Chief Medical Officer	Acquired M	3,500	$7.80	$27.30K	38,771	Direct
15 Oct, 2026	Joana Goncalves	Chief Medical Officer	Disposed S	2,853	$73.89	$210.81K	35,918	Direct
15 Oct, 2026	Joana Goncalves	Chief Medical Officer	Disposed S	1,847	$74.69	$137.96K	34,071	Direct
15 Oct, 2026	Joana Goncalves	Chief Medical Officer	Disposed S	1,400	$75.48	$105.68K	32,671	Direct
15 Oct, 2026	Joana Goncalves	Chief Medical Officer	Disposed S	700	$76.67	$53.67K	31,971	Direct

Showing 1 to 20 of 612 transactions